Story perspectives

New HIV Prevention Injection Safe for Transgender Hormone Therapy

12/17/2025

Summary

Story summary

A study presented at IDWeek 2025 finds that lenacapavir, a new injectable PrEP for HIV prevention, does not adversely interact with hormone therapy for transgender individuals.
The Food and Drug Administration approved lenacapavir in June.
Lenacapavir offers twice-annual injections.
Led by Dr. Jill Blumenthal of the University of California, San Diego, the study analyzed hormone levels in more than 2,000 participants and found no significant changes in estrogen and testosterone after lenacapavir administration, supporting concurrent use with gender-affirming hormone therapy.

1 of 1

Story summary

A study presented at IDWeek 2025 finds that lenacapavir, a new injectable PrEP for HIV prevention, does not adversely interact with hormone therapy for transgender individuals.
The Food and Drug Administration approved lenacapavir in June.
Lenacapavir offers twice-annual injections.
Led by Dr. Jill Blumenthal of the University of California, San Diego, the study analyzed hormone levels in more than 2,000 participants and found no significant changes in estrogen and testosterone after lenacapavir administration, supporting concurrent use with gender-affirming hormone therapy.